Month: August 2025

SINGAPORE, Aug. 25, 2025 (GLOBE NEWSWIRE) — EngageLab launches industry-leading WebPush support for Chrome Extensions, empowering developers and businesses to reach users with real-time, high-impact notifications—no extra permissions, no missed opportunities. 1. Chrome Extensions: The New “Blue Ocean” for Developers and BrandsIn an era of information overload and the relentless pursuit of productivity, browsers have become the central gateway for work, learning, shopping, and social interaction. Chrome extensions are now the “smart switches” at this gateway, enabling users to translate, take notes, block ads, compare prices, manage passwords, and much more—without ever leaving their current page.But Chrome extensions are more than just useful—they’re a booming business opportunity:Deep User Integration: Extensions are always...

        Company Announcement No 37/2025Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk25 August 2025  Dear Sirs Sydbank A/S share buyback programme: transactions in week 34On 26 February 2025 Sydbank A/S announced a share buyback programme of DKK 1,350m. The share buyback programme commenced on 3 March 2025 and will be completed by 31 January 2026. The purpose of the share buyback programme is to reduce the share capital of Sydbank A/S and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under...

TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. LEQEMBI received the European Commission (EC) approval in April 2025 as the first therapy that targets an underlying cause of Alzheimer’s disease (AD). It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD ( collectively referred to as early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes with confirmed...

Sampo plc, stock exchange release, 25 August 2025 at 8:30 am EEST Sampo plc’s share buybacks 22 August 2025                                                        On 22 August 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  2,608 9.92 AQEU    117,609 9.91 CEUX  29,013 9.91 TQEX  176,350 9.91 XHELTOTAL 325,580 9.91  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

Equinor ASA (OSE: EQNR, NYSE: EQNR) announced on 30 April 2025 a cash dividend per share of USD 0.37 for first quarter 2025. The NOK cash dividend per share is based on average USDNOK fixing rate from Norges Bank in the period plus/minus three business days from record date 19 August 2025, in total seven business days. Average Norges Bank fixing rate for this period was 10.1999. Total cash dividend for first quarter 2025 of is consequently NOK 3.7740 per share. On 29 August 2025, the cash dividend will be paid to relevant shareholders on Oslo Børs (Oslo Stock Exchange) and to holders of American Depositary Receipts (“ADRs”) on New York Stock Exchange. This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian...

OSLO, Norway (25 August 2025) – TGS, a leading provider of energy data and intelligence, is pleased to announce the award of a large streamer contract offshore Indonesia, covering approximately 10,000 square kilometers. Much of the project will focus on acquiring 3D seismic data for exploration purposes, with the final phase of approximately one month dedicated to 4D seismic data acquisition for production monitoring. The survey is scheduled to commence in Q4 2025 and will span an estimated total duration of approximately eight months. Kristian Johansen, CEO of TGS, commented, “We are very pleased to have been awarded this significant streamer contract. We will acquire the survey with a purpose-built Ramform designed vessel, equipped with our proprietary GeoStreamer technology, ensuring delivery of high-quality data to the client,...

Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ® in the United States. The suspension follows the FDA’s decision on August 6, 20251 to remove its recommended pause2 in the use of IXCHIQ® in individuals 60 years of age and older based on a thorough investigation of reported SAEs, primarily among elderly individuals with multiple underlying health conditions. The sudden subsequent decision to suspend IXCHIQ® is based on updated VAERS data (Vaccine...

Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to be submitted to U.S. Food and Drug Administration (FDA) by end of 2025August 25, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline data from the pivotal ADAPT SERON study of VYVGART® (IV: efgartigimod alfa-fcab). The study met its primary endpoint (p-value=0.0068), demonstrating that AChR-Ab seronegative gMG patients treated with VYVGART achieved a statistically significant and clinically meaningful...

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting New Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi® and Lusvertikimab Nantes, August 25, 2025, 7:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual General Shareholders’ Meeting, to be held on September 30, 2025, along with a proposed evolution in its governance. This move reinforces the company’s commitment to balanced and proportionate shareholder representation and strategic alignment. The proposed governance framework is in the context of ongoing discussions with concertist shareholders. It aims to ensure international expertise, while maintaining independence and...